## MRNA: Moderna, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 9.4% in upper entry zone (4.0-10.0%), top 6% cross-sectional ranking. Short-term MRS_5 (4.7%) confirms momentum alignment. Strong momentum (+9.2% 5-day acceleration). Outperforming sector by 13.9%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($25.44)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Invesco Ltd. Has $195.92 Million Holdings in Moderna, Inc. $MRNA**
- Source: MarketBeat | 20251208T112635 | Neutral | Relevance: 98%
-  Invesco Ltd. significantly increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 20.7% in the second quarter, now holding 7,101,032 shares valued at approximately $195.92 million. Despite this substantial investment and Moderna beating Q2 earnings estimates, analyst sentiment remains largely cautious with an average "Reduce" rating and a target price of $29.46. The company is currently unprofitable, experiencing a 45.4% year-over-year revenue decline, and has negative margins.

**2. 58,854 Shares in Moderna, Inc. $MRNA Bought by Quantbot Technologies LP**
- Source: MarketBeat | 20251207T104620 | Neutral | Relevance: 98%
- Quantbot Technologies LP recently acquired 58,854 shares of Moderna (NASDAQ:MRNA) in the second quarter, valuing the new stake at approximately $1.624 million. Despite Moderna beating EPS and revenue estimates, its revenue declined year-over-year, and analysts maintain a "Reduce" consensus rating with an average target price of $29.46. Institutional investors and hedge funds hold a significant 75.33% of Moderna's stock.

**3. Moderna (MRNA) Just Reclaimed the 200-Day Moving Average**
- Source: Yahoo Finance | 20251208T140818 | Bullish | Relevance: 98%
-  Moderna (MRNA) has recently moved above its 200-day moving average, signaling a potential long-term bullish trend. The stock has rallied 12.9% over the past four weeks and holds a Zacks Rank #3 (Hold), supported by positive earnings estimate revisions. Investors are advised to consider MRNA for their watchlist due to these strong technical and fundamental indicators.

**4. Lido Advisors LLC Sells 140,814 Shares of Moderna, Inc. $MRNA**
- Source: MarketBeat | 20251208T110835 | Neutral | Relevance: 98%
- Lido Advisors LLC significantly reduced its holdings in Moderna, Inc. by 91.2% in the second quarter, selling 140,814 shares and retaining 13,574 shares valued at $375,000. Other institutional investors also adjusted their positions in Moderna. The article also provides a financial overview of Moderna, including its stock performance, recent earnings, and analyst ratings, which currently lean towards "Reduce" with a consensus target price of $29.46.

**5. Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates**
- Source: Victorville Daily Press | 20251207T120904 | Neutral | Relevance: 98%
-  Moderna reported its third quarter 2025 financial results, with total revenue reaching $1.0 billion despite a 45% decrease from the previous year. The company narrowed its projected 2025 revenue range to $1.6 – $2.0 billion and increased its expected year-end cash balance, while also providing updates on its commercial products (mNEXSPIKE and mRESVIA) and late-stage pipeline, including respiratory and latent vaccines, oncology therapeutics, and rare disease treatments.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 1, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Piper Sandler | $63 | $69 | -9% |
| 2025-11-21 | RBC Capital | $25 | $28 | -11% |
| 2025-11-21 | Leerink Partner | $18 | $15 | +20% |
| 2025-11-10 | B of A Securiti | $21 | $24 | -12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Piper Sandler | reit | Overweight |
| 2025-11-21 | RBC Capital | main | Sector Perform |
| 2025-11-21 | Leerink Partner | main | Underperform |
| 2025-11-10 | B of A Securiti | main | Underperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.00M) |
| Sells | 4 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-1.2%)
- Blackrock Inc.: 7.6% (+3.2%)
- BAILLIE GIFFORD & CO: 5.6% (-1.1%)
- State Street Corpora: 4.4% (-0.9%)
- FMR, LLC: 3.1% (-37.4%)

### Key Risks

1. High short interest (20.0%, 5.5 days to cover): squeeze risk or crowded bearish bet.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +9.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.61 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.9x), low leverage (D/E 0.30). Analyst sentiment negative (3 target cuts vs 1 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.0B |
| Beta | 1.11 |
| 52W Range | $22.28 - $48.92 |
| Short Interest | 20.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.61 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from 0.2% to 9.4% (+9.2% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 94th percentile. MRS_5 at 4.7% confirms short-term momentum alignment. AM_20 at 11.7% shows strong absolute momentum above own 20MA. Outperforming sector by 13.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.3x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 9.42% (CS: 94) | Strong |
| RSI_14 | 62.4 | Neutral |
| MACD Histogram | 0.49 | Bullish |
| vs SMA20 | 1.117x | Above |
| vs SMA50 | 1.087x | Above |
| vs SMA200 | 1.024x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $28.24
- **Stop Loss:** $25.44 (9.9% risk)
- **Target:** $32.44 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 107
- **Position Value:** $3,021.68
- **Portfolio %:** 3.02%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-12 (Est: $-2.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-2.18 | $-0.51 | +76.6% |
| 2025Q2 | $-2.97 | $-2.13 | +28.3% |
| 2025Q1 | $-3.18 | $-2.52 | +20.7% |
| 2024Q4 | $-2.76 | $-2.91 | -5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*